Tocagen Inc (TOCA)

[gr8db8]

The median survival in this trial is nearly double compared to historical data, according to Dr. Chen. In the subgroup, median survival was 14.4 months compared to approximately 8 months for historical controls. In contrast to the ongoing, durable responses observed in this study, patients treated with the chemotherapy lomustine (Gleostine) had an overall response rate of about 4.3%, which, like bevacizumab (Avastin), was not durable and typically lasted a few months.

A limitation of the study is that it was a single-arm trial without a control group.

http://www.ascopost.com/News/58198